Drug intelligence / Profile preview

Lipovenoes + Omegaven

Development stage: Preclinical
Lead developer: Fresenius Kabi
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

Lipovenoes + Omegaven is a combination of two intravenous lipid emulsions used in parenteral nutrition. Omegaven is a fish oil-based lipid emulsion containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), while Lipovenoes is a soybean oil-based lipid emulsion. This combination provides a balanced fatty acid profile with both omega-6 (from Lipovenoes) and omega-3 (from Omegaven) fatty acids. Studies have shown that this combination may help reduce liver enzymes and bilirubin levels in patients receiving parenteral nutrition, particularly in post-abdominal surgery patients.

Beyond the preview

Go deeper on Lipovenoes + Omegaven.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipovenoes + Omegaven.

Explore the full profile